As the world grapples with multiple mental health crises, including depression and anxiety, PTSD, and rising suicide rates, psychedelics have shown great promise in early clinical trials.
But while compounds such as psilocybin, ibogaine, and DMT all are showing signs of being efficacious, they are by no means perfect medicines. All have potential downfalls that limit their ability to meet the massive scale we need to put a dent in the mental health crisis.
Therefore, while it is essential that the pace of study into classical psychedelics continues to ramp up, companies are simultaneously editing the chemical formulas of these entheogens to create better medicines.
Now, there will always be those who argue that there is no point in spending the tens of millions necessary to create new psychedelics, saying that we already have perfect medicines given to us by nature.
This argument is nonsensical. First, as will be expanded upon further in this article, in a medical context, medicines such as psilocybin and ibogaine do indeed have shortcomings. If we can harness the power of science to eliminate them, we should.
Second, many current medicines were originally derived from plants, and then were improved upon over the decades. Take for example ibuprofen, the painkiller found in brands like Advil. Ibuprofen is a synthetic derivative of the natural substance salicylic acid, which is found in the bark of trees such as a willow tree.
The ancients used to chew this bark, or turn it into a brew, to treat pain. But since its synthesis in the early 1900s, scientists have constantly been tweaking the formula to avoid negative side effects such as gastrointestinal irritation. Yet no one in their right mind would argue we go back to chewing on willow bark because it is more natural.
With this in mind, this article aims to shine a spotlight on five next-generation psychedelics that are expected to enter clinical trials this year. Keep in mind that all of these new drugs are closer to the beginning of their scientific study than the end, and any and all claims made by the companies producing them will have to be proven in multiple, rigorous, clinical trials. Furthermore, it is far too early to tell which of these will be the most efficacious.
Also note that this list is not exhaustive, and the compounds are not presented in any particular order.
18-MC, now being rebranded as MM-110, is perhaps the furthest advanced in the long line of next-generation psychedelics. Set to enter Phase 2a efficacy trials this quarter, attempting to treat Opioid Use Disorder, the MindMed (Nasdaq: MNMD. NEO: MMED) molecule already completed a Phase 1 safety trial which showed the compound to be well tolerated, without any serious adverse events.
MM-110as it is now knownis a synthetic molecule based on the extremely hallucinogenic ibogaine, which is found in the iboga shrub in Africa. While some early studies have shown ibogaine may be effective in treating various addictions, the medicine does carry with it some downsides.
First is the long psychedelic experience. An ibogaine hallucination can last upwards of 48 hours. And while this may be fine in a ritual setting, in a medical one it raises many problems, not the least of which would be the cost of monitoring a patient for two days.
The next issue is a medical one; use of ibogaine can lead to cardiovascular side effects and there are even casesalbeit rareof ibogaine use leading to cardiac arrest and death.
18-MCexcuse me, MM-110claims that it has solved both of these issues. First, the compound does not cause a hallucination. A patient could take MM-110 like they would any other prescription. Second, MindMed claims that the cardiovascular side effects have been eliminated.
If these claims hold true as MM-110 makes its way through the clinical trial process, and if it is found to be effective in treating Opioid Use Disorderand eventually perhaps other addictions as wellthen 18-MC could be a game-changer in addiction treatment.
CYB003 is Cybins (NYSE: CYBN, NEO: CYBN) next-generation psilocybin. Assuming regulatory approval, they intend to start the Phase 1 portion of their Phase 1/2a trial in mid-2022. This trial will attempt to treat Major Depressive Disorder.
While psilocybin has had some very promising results in Phase 2 clinical trials, mostly attempting to treat forms of depression, it is not a perfect medicine. In particular, there are two problems that medical psilocybin possesses.
The first is the long duration of the experience. While not nearly as long as ibogaine, a psilocybin experience can still last upwards of 6 to 8 hours. Included in this is the long time it takes for the compound to reach a therapeutic effect after ingestion, often at around an hour. This would make a therapy session very expensive and may price out lower-income people.
Next, is the variability of effect between individuals. In other words, similar-sized people could ingest the same amount of psilocybin and metabolize it differently, causing vastly different intensities of effect. This can also lead to side effects in certain populations.
Cybin says that their pre-clinical evidence shows that CYB003 counteracts these issues. First, in duration of effect, Cybin says that their next-generation psilocybins onset action is twice as fast as the original, and the overall experience may likewise be halved. This would greatly expand accessibility.
On the safety side, Cybin says that the effects of CYB003 are less variable than traditional psilocybin, which they measured by looking at plasma concentration levels. In other words, using CYB003 would cause similar effects in different individuals. Combine this with improved brain penetration ratios, which again were found in preclinical animal studies, and CYB003 may lead to fewer side effects and safer dosing options and more predictable patient outcomes.
SPL028 is Small Pharmas (TSXV: DMT, OTCQB: DMTTF) next-generation DMT. Assuming regulators are satisfied, Small Pharma hopes to launch a Phase 1 safety trial in the second half of 2022.
Unlike ibogaine and psilocybin, DMTs therapeutic issue is not that it lasts too long, but rather that its effects are too short. Traditionally, a DMT experience, whether administered through smoking or by IV, only lasts up to 20 minutesand that is on the generous side.
While there has been much less study on DMT than psilocybinin fact earlier this year Small Pharma initiated the worlds first Phase 2 trial on DMTit is hypothesized that the short duration may not be sufficient for a clinical effect to take hold.
SPL028 will last longer than regular DMT, but it will still be significantly shorter than a psilocybin trip. Essentially, Small Pharma hopes to find the sweet spot in terms of duration. Their Phase 1 trial will also test whether an IV delivery or an intramuscular delivery is best.
It is also important to note that Cybin is likewise planning on launching a pilot study this year on their own modified DMT candidate, CYB004, which also aims to lengthen the experience.
FT-104 is Field Trip Healths (Nasdaq: FTRP, TSX: FTRP) first next-generation psychedelic, which they aim to have in a Phase 1 clinical trial before the end of the first half of 2022. FT-104 is a pro-drug to the little-known psychedelic, 4-HO-DiPT, which means that FT-104 metabolizes in the body to form 4-HO-DiPT.
Once it makes its way out of Phase 1 and into later phase efficacy tests, Field Trip wants to test treating Treatment-Resistant Depression and Postpartum Depression with FT-104.
4-HO-DiPT is a psychedelic that is similar in effect to psilocybin, but with a shorter duration of effect, only lasting between 2-3 hours. As mentioned above, this could make it more practical to use in a clinical setting.
In terms of practical differences from 4-HO-DiPT, Ft-104 is more soluble, which may make it easier to use as a medicine.
Note, soon Field Trip Health will be dividing into two separate companies. When this happens, FT-104 and all other drug discovery programs will be under the purview of the new company, Reunion Neuroscience.
MEAI, unlike all other molecules on this list, is not based on a current psychedelic. Rather, Clearmind Medicine (CSE: CMND, OTC Pink: CMNDF) has a more unique molecule on its hands.
Aiming to enter Phase 1 trials by the end of this year, MEAI will attempt to treat Alcohol Use Disorder.
Essentially, according to Mark Haden, the VP of Business Development for Clearmind, MEAI induces the sensation of satiation in a subject. This means if a person takes MEAI in conjunction with alcohol, after several drinks the person will feel done with the substance, and not feel the need to have another.
Mr. Haden uses the analogy of having eaten two rich cheesecakes, and then someone places a third one down in front of you. Sure, you could have another. But you dont want to. You are satiated.
This is interesting, since if its proven to work MEAI could be used with a prescription from a doctor, but it could also possibly be available given regulatory approval as an alcohol substitute that anyone could buy.
The subjective effects of MEAI are said to feel similar to one to two beers after the first and second dose of it, and more similar to a low dose of MDMA after a third dose. Interestingly, after the third dose, Clearmind says that the prospect of having more is unsavory.
If proven to work all we have so far is anecdotal and animal evidence MEAI could revolutionize alcohol addiction treatment.
Interested in investing but need help researching stocks? Check out Wealth Research Groups FREE stock report: Ultimate Forever Stocks: Hold and Add More for the Remainder of Your Life!
This FREE stock report dives into EIGHT stocks that Wealth Research Group believes will transform your portfolio.
Completely FREE, Wealth Research Group wont spam you and will NEVER ask for your credit card. So what do you have to lose? Plus, by downloading the report, you support Psychedelic Spotlight, so it is a win-win!
Download Now!
View post:
5 Next-Generation Psychedelics Entering Clinical Trials This Year - Psychedelic Spotlight
- Vermont Senate Passes Psychedelic Working Group Bill To Study How Entheogens Might Benefit Physical And Mental ... - Marijuana Moment - March 31st, 2024 [March 31st, 2024]
- Melissa Etheridge's New Book and Play Delve Into Her Son's Opioid ... - CelebStoner - October 29th, 2023 [October 29th, 2023]
- Walking the poison path: An interview with Coby Michael - The Wild Hunt - October 29th, 2023 [October 29th, 2023]
- Entheogenic drugs and the archaeological record - Wikipedia - April 14th, 2023 [April 14th, 2023]
- Learn All About The Top 10 Entheogens - Zamnesia Blog - February 20th, 2023 [February 20th, 2023]
- Entheogens and Psychedelics (including Ayahuasca, LSD, Peyote ... - December 12th, 2022 [December 12th, 2022]
- Terence McKenna - Wikipedia - October 23rd, 2022 [October 23rd, 2022]
- Enlightenment (spiritual) - Wikipedia - October 21st, 2022 [October 21st, 2022]
- Shamanism - Wikipedia - October 17th, 2022 [October 17th, 2022]
- The History Of: Hallucinogens, Psychedelics & Entheogens - August 25th, 2022 [August 25th, 2022]
- How Does Sound Therapy Enhance the Psychedelic Experience? - Psychedelic Spotlight - July 31st, 2022 [July 31st, 2022]
- Could we please have some consistency in our drug laws - Mail and Guardian - July 3rd, 2022 [July 3rd, 2022]
- Filament Health and Jaguar Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications - Yahoo Canada... - June 11th, 2022 [June 11th, 2022]
- Mental Health Startup Journey Colab Aims To Develop Mescaline As An FDA-Approved Treatment For Alcohol Use Disorder - Forbes - April 29th, 2022 [April 29th, 2022]
- Breaking down the decrim movement: Discoveries, doubts and personal ins & outs - Aspen Daily News - April 29th, 2022 [April 29th, 2022]
- Aztec use of entheogens - Wikipedia - March 29th, 2022 [March 29th, 2022]
- The Michigan Decriminalization of Psilocybin Mushrooms and Other Plants and Fungi Initiative Has Been Approved For Circulation As A Ballot Initiative... - February 24th, 2022 [February 24th, 2022]
- 5 Black Pioneers Combatting the Whitewashing of Psychedelics - Psychedelic Spotlight - February 17th, 2022 [February 17th, 2022]
- From Mycophobia to Mycophilia - The McGill Daily - The McGill Daily - February 17th, 2022 [February 17th, 2022]
- Entheogens and Plant Medicine: An Introduction Microdose - Microdose Psychedelic Insights - February 9th, 2022 [February 9th, 2022]
- Schumer Gives Update On Federal Marijuana Legalization And Banking In Meeting With Equity Advocates - Marijuana Moment - February 1st, 2022 [February 1st, 2022]
- USDA Teams Up With Cornell University For Hemp Education Webinar Series - Marijuana Moment - February 1st, 2022 [February 1st, 2022]
- Ohio Lawmakers Will Be Forced To Consider Marijuana Legalization As State Validates Activist Signatures - Marijuana Moment - February 1st, 2022 [February 1st, 2022]
- Psilocybin: Following in the Footsteps of Cannabis Along the Path to Legality - JD Supra - January 29th, 2022 [January 29th, 2022]
- What ketamine therapy taught me about my Jewish intergenerational trauma - Forward - January 29th, 2022 [January 29th, 2022]
- Debunking Myths and Misconceptions of the Psychedelics Industry - Rolling Stone - January 9th, 2022 [January 9th, 2022]
- What are you most excited for in Washtenaw County in 2022? - Concentrate - December 15th, 2021 [December 15th, 2021]
- Looking Into The Florida Bill That Proposes Decriminalization Of Psychedelics (And Every Other Illegal Dr - Benzinga - December 15th, 2021 [December 15th, 2021]
- The Wisdom of Agnosticism - The Humanist - December 15th, 2021 [December 15th, 2021]
- What Are Psychedelic Drugs (Hallucinogenics)? | Leafly - November 28th, 2021 [November 28th, 2021]
- Cannabis & Marijuana Education: Learn All About Weed | Leafly - November 28th, 2021 [November 28th, 2021]
- Vex - Destinypedia, the Destiny wiki - November 11th, 2021 [November 11th, 2021]
- Seattle City Council wants to decriminalize 'magic ... - November 11th, 2021 [November 11th, 2021]
- Tonight at 11: The unseen side of magic mushrooms, from moms to home growers - KIRO Seattle - November 11th, 2021 [November 11th, 2021]
- Guide to Entheogens: Plants, Therapy, Medicine - October 30th, 2021 [October 30th, 2021]
- What are entheogens and which are the best ones - October 30th, 2021 [October 30th, 2021]
- An upcoming election, pay requirement, and holiday, this week - KUOW News and Information - October 30th, 2021 [October 30th, 2021]
- Congressman Says He'll Bring The Psychedelics Reform Movement To Capitol Hill 'This Year' - Marijuana Moment - October 7th, 2021 [October 7th, 2021]
- From Cannabis MSO To Drug Development: Goodness Growth Wants To Understand Traditional Psychedelics Use - - Benzinga - September 16th, 2021 [September 16th, 2021]
- Jarvis Brookfield on his psychedelic paintings, dream-like states and what it means to be human - Creative Boom - September 12th, 2021 [September 12th, 2021]
- Oregon Psilocybin Panel Teams Up With Harvard To Research Psychedelic History And Impacts Of Reform - Marijuana Moment - September 12th, 2021 [September 12th, 2021]
- National Hemp Association Asks Congress To Budget $1 Billion To Support Industry Innovation - Marijuana Moment - September 12th, 2021 [September 12th, 2021]
- Psychedelic Drug Therapy: Tips and Support for the Experience - Greatist - August 28th, 2021 [August 28th, 2021]
- University of Michigan police say safety will be top priority at psychedelic shroom festival - MLive.com - August 22nd, 2021 [August 22nd, 2021]
- Two Years After Oakland's Psychedelic Decrim, What's Been the Impact? - Filter - August 4th, 2021 [August 4th, 2021]
- Psychedelics Decriminalization Advancing In Three More Cities, Spanning From Coast To Coast - Marijuana Moment - August 4th, 2021 [August 4th, 2021]
- Witch City Tarot & Divination Gathering | Coby Michael Ward - Patheos - July 29th, 2021 [July 29th, 2021]
- With Push From New Nonprofit, Arcata City Council Will Soon Consider a Resolution That Would Decriminalize Psychedelic Plants and Fungi in Arcata -... - July 7th, 2021 [July 7th, 2021]
- Group Hopes to Decriminalize Entheogens (Psychoactive Plant Substances) Within Arcata City Limits Redheaded Blackbelt - Redheaded Blackbelt - July 5th, 2021 [July 5th, 2021]
- Winners of Columbia@Roundabout's 2021 New Play Reading Series Announced - Broadway World - June 24th, 2021 [June 24th, 2021]
- Biden said he'd cut down on unemployment benefits, but he really might reinstate a pre-pandemic job-seeking policy The Madison Leader Gazette - The... - May 11th, 2021 [May 11th, 2021]
- The psychedelic revolution is coming. Psychiatry may never be the same - bdnews24.com - May 11th, 2021 [May 11th, 2021]
- Native Tribes Should Have More Say in the Psychedelic Movement - Green Entrepreneur - April 29th, 2021 [April 29th, 2021]
- Red Light Holland and Headland West Indies Lead #SVGStrong, a Relief Effort in St. Vincent and the Grenadines - InvestorIntel - April 29th, 2021 [April 29th, 2021]
- Jews, Christians, and Muslims Are Reclaiming Ancient Psychedelic Practices, And That Could Help With Legalization - Rolling Stone - April 25th, 2021 [April 25th, 2021]
- Psychedelic Experience launches new website to help navigate the world of psychedelics - PRNewswire - April 25th, 2021 [April 25th, 2021]
- Zide Door Oaklands Church of Entheogenic Plants - April 15th, 2021 [April 15th, 2021]
- Opinion | Is it time for Seattle to decriminalize shrooms and psychedelics? - Crosscut - April 15th, 2021 [April 15th, 2021]
- Following Local Successes, Cambridge State Rep. Puts Forward Bills on Controlled Substance Reform | News - Harvard Crimson - March 29th, 2021 [March 29th, 2021]
- The Potential (and Peril) of Legalizing Psychedelics - Progressive.org - January 1st, 2021 [January 1st, 2021]
- Oakland continues move to protect entheogen plants - The Leaf Online - September 18th, 2020 [September 18th, 2020]
- The Only Obstacle To A Healthy World Is Government Secrecy And Propaganda - Scoop.co.nz - July 21st, 2020 [July 21st, 2020]
- There's More to the CHOP Than What the Media Will Have You Believe - Study Breaks - July 21st, 2020 [July 21st, 2020]
- Entheogens | Sacred Geometry - June 15th, 2020 [June 15th, 2020]
- Entheogen - Wikipedia - May 4th, 2020 [May 4th, 2020]
- The Return Trip: Psychedelics may come back from the abyss of illegality - Valley Advocate - November 23rd, 2019 [November 23rd, 2019]
- How San Francisco's Summer of Love sparked religious movements - The Oakland Press - August 25th, 2017 [August 25th, 2017]
- Outside the Box - HuffPost - August 13th, 2017 [August 13th, 2017]
- 'Summer of Love' shaped American lives, spiritual expression - Houston Chronicle - July 29th, 2017 [July 29th, 2017]
- The Summer of Love was more than hippies and LSD it was the start of modern individualism - The Independent - July 24th, 2017 [July 24th, 2017]
- How San Francisco's Summer of Love sparked today's religious movements - Religion News Service - July 22nd, 2017 [July 22nd, 2017]
- The Poisoner: Pharmakos and Veneficus-Poisoner's Apothecary - Patheos (blog) - July 19th, 2017 [July 19th, 2017]
- The Summer of Love was more than hippies and LSD it was the start of modern individualism - Metro Newspaper UK - July 8th, 2017 [July 8th, 2017]
- The Summer of Love was more than hippies and LSD it was the ... - The Conversation UK - July 7th, 2017 [July 7th, 2017]
- Entheogen - PsychonautWiki - July 1st, 2017 [July 1st, 2017]
- The History and Possibilities of Putting Weed in Your Witchcraft - Seattle Weekly - June 29th, 2017 [June 29th, 2017]
- Entheogens : Al-Kemi : spagyrics and alchemy - June 27th, 2017 [June 27th, 2017]
- Virtual Reality Takes Consciousness Research into Mystic Realms of the Divine Play - The Sociable - June 26th, 2017 [June 26th, 2017]
- Entheogen - June 15th, 2017 [June 15th, 2017]
- Entheogens | Drug War Facts - June 5th, 2017 [June 5th, 2017]